Endo International plc – (NASDAQ:ENDP) (TSE:ENL) – Research analysts at Leerink Swann upped their Q4 2017 earnings per share estimates for shares of Endo International in a research note issued to investors on Thursday. Leerink Swann analyst A. Fadia now forecasts that the company will post earnings of $0.58 per share for the quarter, up from their prior estimate of $0.57. Leerink Swann currently has a “Outperform” rating and a $12.00 target price on the stock. Leerink Swann also issued estimates for Endo International’s Q2 2018 earnings at $0.76 EPS, Q3 2018 earnings at $0.71 EPS, Q4 2018 earnings at $0.83 EPS, FY2020 earnings at $2.88 EPS, FY2021 earnings at $2.62 EPS and FY2022 earnings at $2.84 EPS.
Several other analysts also recently weighed in on the company. Zacks Investment Research downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Monday, January 15th. BidaskClub downgraded Endo International from a “hold” rating to a “sell” rating in a research note on Thursday, January 11th. Cantor Fitzgerald set a $7.00 price target on Endo International and gave the stock a “hold” rating in a research note on Thursday, January 11th. Mizuho restated a “buy” rating and issued a $12.00 price target (down previously from $14.00) on shares of Endo International in a research note on Wednesday, January 3rd. Finally, ValuEngine downgraded Endo International from a “buy” rating to a “hold” rating in a research note on Sunday, December 31st. Three analysts have rated the stock with a sell rating, fourteen have given a hold rating, five have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The stock has a consensus rating of “Hold” and an average price target of $10.79.
Endo International (NASDAQ:ENDP) (TSE:ENL) last posted its quarterly earnings results on Thursday, November 9th. The company reported $0.91 earnings per share for the quarter, topping the consensus estimate of $0.85 by $0.06. The company had revenue of $786.90 million for the quarter, compared to the consensus estimate of $794.93 million. Endo International had a positive return on equity of 66.98% and a negative net margin of 126.97%. The firm’s quarterly revenue was down 11.0% compared to the same quarter last year. During the same quarter in the prior year, the business posted $1.01 EPS.
A number of institutional investors and hedge funds have recently modified their holdings of ENDP. Diamond Hill Capital Management Inc. boosted its stake in Endo International by 46.8% during the 3rd quarter. Diamond Hill Capital Management Inc. now owns 716,670 shares of the company’s stock valued at $6,138,000 after purchasing an additional 228,426 shares during the last quarter. River & Mercantile Asset Management LLP boosted its stake in Endo International by 116.3% during the 3rd quarter. River & Mercantile Asset Management LLP now owns 358,540 shares of the company’s stock valued at $3,071,000 after purchasing an additional 192,790 shares during the last quarter. Van ECK Associates Corp boosted its stake in Endo International by 67.1% during the 3rd quarter. Van ECK Associates Corp now owns 340,991 shares of the company’s stock valued at $2,921,000 after purchasing an additional 136,873 shares during the last quarter. Quantitative Investment Management LLC purchased a new stake in Endo International during the 2nd quarter valued at $1,344,000. Finally, Nomura Holdings Inc. purchased a new stake in Endo International during the 2nd quarter valued at $745,000. Institutional investors and hedge funds own 93.07% of the company’s stock.
TRADEMARK VIOLATION WARNING: This story was reported by American Banking News and is owned by of American Banking News. If you are viewing this story on another website, it was illegally stolen and republished in violation of United States & international trademark and copyright law. The legal version of this story can be accessed at https://www.americanbankingnews.com/2018/01/29/endo-international-plc-endp-to-post-q4-2017-earnings-of-0-58-per-share-leerink-swann-forecasts.html.
Endo International Company Profile
Endo International PLC, formerly Endo Health Solutions Inc is a specialty healthcare solutions company focused on branded and generic pharmaceuticals, devices and services. The Company has a portfolio of branded pharmaceuticals that includes brands, such as Lidoderm, Opana ER, Voltaren Gel, Percocet, Frova, Supprelin LA, Vantas, Valstar and Fortesta Gel.
Receive News & Ratings for Endo International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Endo International and related companies with MarketBeat.com's FREE daily email newsletter.